288 related articles for article (PubMed ID: 18048816)
21. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
[TBL] [Abstract][Full Text] [Related]
22. Physician variation in management of low-risk prostate cancer: a population-based cohort study.
Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD
JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650
[TBL] [Abstract][Full Text] [Related]
23. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
24. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
26. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
27. Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.
Ellis SD; Nielsen ME; Carpenter WR; Jackson GL; Wheeler SB; Liu H; Weinberger M
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):173-81. PubMed ID: 25849354
[TBL] [Abstract][Full Text] [Related]
28. The truth is out there: an overall perspective on androgen deprivation.
Hellerstedt BA; Pienta KJ
Urol Oncol; 2003; 21(4):272-81. PubMed ID: 12954498
[TBL] [Abstract][Full Text] [Related]
29. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
[TBL] [Abstract][Full Text] [Related]
30. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
31. External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation.
Koontz BF; Lee WR
Arch Esp Urol; 2011 Oct; 64(8):858-64. PubMed ID: 22052767
[TBL] [Abstract][Full Text] [Related]
32. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.
Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S
JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987
[TBL] [Abstract][Full Text] [Related]
33. Novel hormonal therapy for castration-resistant prostate cancer.
Sternberg CN
Ann Oncol; 2012 Sep; 23 Suppl 10():x259-63. PubMed ID: 22987973
[No Abstract] [Full Text] [Related]
34. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
Gilbert SM; Kuo YF; Shahinian VB
Urol Oncol; 2011; 29(6):647-53. PubMed ID: 19926311
[TBL] [Abstract][Full Text] [Related]
35. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer.
Dell'Oglio P; Bishr M; Boehm K; Trudeau V; Larcher A; Tian Z; Sosa J; Moschini M; Saad F; Capitanio U; Briganti A; Graefen M; Montorsi F; Karakiewicz PI
Eur Urol Focus; 2018 Dec; 4(6):834-841. PubMed ID: 28753853
[TBL] [Abstract][Full Text] [Related]
36. Hormone therapy in advanced prostate cancer.
Forster TH; Stoffel F; Gasser TC
Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
[No Abstract] [Full Text] [Related]
37. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
38. Complete androgen blockade for the treatment of prostate cancer.
Labrie F; Dupont A; Belanger A
Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
[No Abstract] [Full Text] [Related]
39. Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy.
Richards KA; Liou JI; Cryns VL; Downs TM; Abel EJ; Jarrard DF
J Urol; 2018 Dec; 200(6):1256-1263. PubMed ID: 29940252
[TBL] [Abstract][Full Text] [Related]
40. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
